Brief: Adverum Biotechnologies Reports First Quarter 2023 Financial Results

Adverum Biotechnologies

11/05/2023 21:52

Adverum Biotechnologies Inc  ADVM.O :
    * ADVERUM BIOTECHNOLOGIES REPORTS FIRST QUARTER 2023
FINANCIAL
RESULTS
    * ADVERUM BIOTECHNOLOGIES - FULL ENROLLMENT OF PHASE 2 LUNA
TRIAL
IN WET AGE-RELATED MACULAR DEGENERATION (WET AMD) IS ANTICIPATED
IN H2 OF 2023
    * CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS WERE
$164.3
MILLION AS OF MARCH 31, 2023
    * EXPECTS THE MARCH 31, 2023 CASH POSITION TO FUND
OPERATIONS INTO
2025
    * QTRLY LOSS PER SHARE $0.29
    * Q1 EARNINGS PER SHARE VIEW $-0.32 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNXRGQPk 
Further company coverage:  ADVM.O